November 15th, 2026Crossover to Bezuclastinib Plus Sunitinib Improves Disease Control in Pretreated GISTCrossover to bezuclastinib plus sunitinib after progression on sunitinib improved PFS and responses in GIST in phase 3 PEAK, with no new safety signals.Read more
November 12th, 2026Neoadjuvant Eftilagimod Alfa Regimen Yields 81% 12-Month DFS in Soft Tissue SarcomaEftilagimod alfa plus pembrolizumab and radiotherapy yielded 81.1% disease-free survival at 12 months in patients with resectable soft tissue sarcoma.Read more